Merck Gains Clinical Oncology Program Through Aton Acquisition; Lead Agent In Phase II
This article was originally published in The Pink Sheet Daily
Executive Summary
Aton’s suberoylanilide hydroxamic acid would be Merck’s only oncologic in later-stage clinical trials. The acquisition is the second recent example of how Merck is branching into new therapeutic areas.
You may also be interested in...
Merck Enhances Aura Of Cancer Research With Vertex Aurora Kinase Inhibitor Deal
VX-680 is ready to begin Phase I trials; aurora kinase inhibitor could have applicability in a number of cancer types. Merck will pay $20 mil. up front and as much as $350 mil. in milestones to Vertex.
Merck Enhances Aura Of Cancer Research With Vertex Aurora Kinase Inhibitor Deal
VX-680 is ready to begin Phase I trials; aurora kinase inhibitor could have applicability in a number of cancer types. Merck will pay $20 mil. up front and as much as $350 mil. in milestones to Vertex.
Merck/Lundbeck Gaboxadol NDA Planned For 2007; Merck Gets Fourth Phase III NME
The $270 mil. licensing deal with Lundbeck will help boost Merck's pipeline after two significant late-stage setbacks in 2003. The GABA-A receptor agonist gaboxadol would be Merck's entry into the sleep disorder market.